No Data
No Data
No Data
No Data
No Data
Goldman Sachs: Maintaining the Xiaomi Group-W (01810) “Buy” Rating Target Price of HK$20
Goldman Sachs believes that the Xiaomi Group's electric vehicle revenue and gross profit forecast has room for further improvement.
Zhitong Finance02:17 ET
Changes in Hong Kong stocks | Cinda Biotech (01801) rose more than 6%, demand for weight loss products surged, and the company's product, Maxidopeptide, has submitted a listing application for weight loss indications
Cinda Biotech (01801) rose more than 6%. As of press release, it rose 6.22% to HK$38.4, with a turnover of HK$299 million.
Zhitong FinanceApr 24 03:26 ET
The biomedical sector gained strength in the afternoon, and Pharmaceutical Federation (02268) rose 8.59%. Institutions say the industry still has structural growth this year
Jinwu Financial News | The biomedical sector gained strength in the afternoon, with Pharmaceuticals (02268) up 8.59%, Rongchang Biotech (09995) up 6.53%, Cinda Biotech (01801) up 6.48%, Cansino Biotech (06185) 6.4%, Viva Biotech (01873) 5.88%, Hehuang Pharmaceutical (00013) up 5.58%, and Kang Fang Biotech (09926) up 5.41%. Huaxin Securities said that the growth of the industry in the first quarter of 2024 was clearly affected by the base for the same period, such as retail pharmacies, POCT, etc., and the outlook is for the whole of 2024.
金吾財訊Apr 23 01:51 ET
Changes in Hong Kong stocks | Cinda Biotech (01801) rose more than 5% in the afternoon, and the cholangiocarcinoma treatment drug Dabertan was approved for listing in Macau, China
Cinda Biotech (01801) rose more than 5% in the afternoon. As of press release, it was up 5.15% to HK$35.7, with a turnover of HK$131 million.
Zhitong FinanceApr 23 01:30 ET
More contests are coming! Global Data: 13 new weight loss drugs are expected to be launched by 2029
Pharmacists are preparing to launch around 13 new weight loss treatments in the US within the next five years due to a surge in demand for weight loss products, according to a new report from global data analysis and consulting firm Global Data.
Zhitong FinanceApr 22 03:29 ET
[Broker Focus] CMB International expects China's pharmaceutical industry to return to healthy growth this year
Jinwu Financial News | CMB International said that since the beginning of the year, the MSCI China Healthcare Index has fallen 22.7%, outperforming the MSCI China Index by 23.3%. Looking ahead to 2024, China's pharmaceutical industry is expected to return to healthy growth as industry regulation is normalized and the impact of the COVID-19 base gradually subsides. The bank continues to be optimistic about BeiGene (06160), Cinda Biotech (01801), Columbotai (06990), Giant Biotech (02367), Gushengtang (02273), and Mindray Healthcare (300760). Additionally, it is recommended to focus on high-dividend stocks with steady performance, such as Regal Healthcare
金吾財訊Apr 16 02:51 ET
No Data
No Data